Special Issue

Strategies against Bacterial Biofilm Formation

Message from the Guest Editors

Biofilm is a mysterious multicellular bacterial form of life that has not revealed all its secrets. It represents an adaptive and quite common bacterial response to several stress factors, which confer an important protection to bacteria. Biofilm formation starts with bacterial adhesion on a surface, further reinforced by matrix synthesis to finally reach a complex structure. Biological tissues such as bones, lungs or even implanted devices are frequently the siege of biofilm colonization. Furthermore, biofilm implication in numerous diseases is regularly reevaluated upwards. As biofilms are tolerant to any known antibiotics, they represent a major issue for public health. This Special Issue seeks manuscripts that focus on the development of antibiofilm strategies; chemical or natural compounds, physical techniques, functionalized materials or other innovative antibiofilm processes are welcomed.

- Biofilms mechanisms;
- Identification of bacterial targets to fight against biofilm;
- Antibiofilm molecules:
- Synergy of antimicrobial and antibiofilm molecules;
- In vitro or in vivo biofilm models development.

Guest Editors

Dr. Fany Reffuveille

Université de Reims Champagne-Ardenne, EA4691 BIOS lab, Reims, France

Dr. Marius Colin

Université de Reims Champagne-Ardenne, EA4691 BIOS lab, Reims, France

Deadline for manuscript submissions

closed (15 April 2022)



an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



mdpi.com/si/76721

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

